Header Logo

Connection

JOSEPH JANKOVIC to Parkinsonian Disorders

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Parkinsonian Disorders.
JOSEPH JANKOVIC
Connection Strength
8.685
Parkinsonian Disorders
  1. Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024 01 15; 456:122810.
    View in: PubMed
    Score: 0.829
  2. Editorial "Parkinsonism across the spectrum of movement disorders and beyond". J Neurol Sci. 2022 Feb 15; 433:120013.
    View in: PubMed
    Score: 0.714
  3. The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci. 2022 Feb 15; 433:120012.
    View in: PubMed
    Score: 0.714
  4. Parkinsonism and tremor syndromes. J Neurol Sci. 2022 Feb 15; 433:120018.
    View in: PubMed
    Score: 0.714
  5. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
    View in: PubMed
    Score: 0.610
  6. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016 Mar; 12(3):175-85.
    View in: PubMed
    Score: 0.484
  7. Psychogenic (functional) parkinsonism. Handb Clin Neurol. 2016; 139:259-262.
    View in: PubMed
    Score: 0.479
  8. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
    View in: PubMed
    Score: 0.463
  9. Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry. 2011 Dec; 82(12):1300-3.
    View in: PubMed
    Score: 0.356
  10. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
    View in: PubMed
    Score: 0.355
  11. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011 Jul; 26(8):1556-8.
    View in: PubMed
    Score: 0.346
  12. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
    View in: PubMed
    Score: 0.294
  13. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008 Dec 26; 448(2):180-3.
    View in: PubMed
    Score: 0.291
  14. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005 Aug 23; 65(4):651-2.
    View in: PubMed
    Score: 0.234
  15. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005 Jul 15; 382(3):297-9.
    View in: PubMed
    Score: 0.228
  16. Drug-induced parkinsonism: diagnosis and treatment. Expert Opin Drug Saf. 2024 Dec; 23(12):1503-1513.
    View in: PubMed
    Score: 0.221
  17. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004 Apr; 19(4):465-9.
    View in: PubMed
    Score: 0.212
  18. The role of the PLA2G6 gene in neurodegenerative diseases. Ageing Res Rev. 2023 08; 89:101957.
    View in: PubMed
    Score: 0.200
  19. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001 Oct; 8(2):109-21.
    View in: PubMed
    Score: 0.178
  20. Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016 Jan; 73(1):68-75.
    View in: PubMed
    Score: 0.120
  21. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg. 2014 Jul-Aug; 82(1-2):241.e1-4.
    View in: PubMed
    Score: 0.102
  22. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012 Sep; 11(6):768-73.
    View in: PubMed
    Score: 0.095
  23. Peripherally induced movement disorders. Neurol Clin. 2009 Aug; 27(3):821-32, vii.
    View in: PubMed
    Score: 0.077
  24. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr; 79(4):368-76.
    View in: PubMed
    Score: 0.070
  25. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007 Mar 15; 22(4):546-9.
    View in: PubMed
    Score: 0.065
  26. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.064
  27. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
    View in: PubMed
    Score: 0.052
  28. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003 Oct; 18(10):1190-2.
    View in: PubMed
    Score: 0.051
  29. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000 Feb; 101(2):79-84.
    View in: PubMed
    Score: 0.040
  30. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.